Biocom’s 5th Annual Global Life Science Partnering Conference has scheduled an impressive list of senior industry leaders to provide insight on relevant topics.
Here are just a few of the speakers we don’t want to miss.
Under Michael’s leadership, Ambit Biosciences negotiated an amicable conclusion to a legacy collaborative development agreement with Astellas, concluded a Series E financing, completed the company’s initial public offering, initiated a registrational Phase 3 trial for their lead drug, Quizartinib, and successfully closed the transaction with Daiichi Sankyo in Nov, 2014.
Mike is Former President & CEO of Lumena Pharmaceuticals Inc., Chairman and chief executive officer at Reneo Pharmaceuticals, Inc., has 40 years of experience in the pharmaceutical and biotechnology industries, and is a venture partner at Pappas Ventures.
Richard is Senior VP of Corporate Development, Biogen Idec, Inc., specializing in discovering, developing, and delivering therapies for the treatment of neurodegenerative, hematologic and autoimmune diseases to patients worldwide.
Sylvaine is head of the Sanofi External Science & Partnering organization, US West. In the Western US and Canada, her team is responsible for cultivating relationships and searching and evaluating the technical robustness and strategic fit of innovative partnering opportunities from academic institutions, biotech companies, and non-profit-organizations.
Iain is Senior Vice President of Business Development & Licensing for Merck Research Laboratories. He has more than 20 years of experience in pharmaceutical research, drug discovery, scientific and technology licensing, start-up company leadership, consultant to numerous biotech and venture capital organizations.
Ted is a pharmaceutical veteran with nearly 30 years of industry experience. Under Mr. Schroeder’s leadership as President and CEO, Cadence Pharmaceuticals developed and marketed Ofirmev (IV acetaminophen injection) for the treatment of pain and fever in hospitalized adults and children. Schroeder was named the EY Entrepreneur of the Year (life sciences) for the San Diego region and in November was recognized as a national finalist in the life sciences category.
Barbara is Vice President of External R&D Innovation for Pfizer Inc. and has more than 25 years in the health care industry. At Selective Genetics, she co-invented and helped develop the targeted gene therapy program, both viral and non-viral.
Charles is President & CEO of TRACON Pharmaceuticals, Inc. He led the development of Sutent® in kidney cancer at Pfizer, Inc., which was approved for the treatment of advanced kidney cancer in 2006. Dr. Theuer also held senior positions at IDEC Pharmaceuticals prior to its merger with Biogen and the National Cancer Institute developing both small molecules and biologics (including Zevalin® and Rituxan®).
Biocom’s Global Life Science Partnering Conference takes place from February 25-26 at the gorgeous Lodge at Torrey Pines. George Evashko, Director of Business Development, is Parallel 6’s main point of contact for all things BIOCOM (responsible for our membership and personally part of all committees).
Participate in the conversation on social media. Follow us on Twitter @Parallel6 and use the hashtag #BiocomPartnering to post photos and updates.